Gene Function in Bone Marrow Cells From Patients With Fanconi Anemia and From Healthy Participants
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00896740|
Recruitment Status : Terminated
First Posted : May 12, 2009
Last Update Posted : December 4, 2017
RATIONALE: Studying samples of bone marrow from patients with Fanconi anemia and from healthy participants in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to Fanconi anemia.
PURPOSE: This laboratory study is evaluating gene function in bone marrow cells from patients with Fanconi anemia and from healthy participants.
|Condition or disease||Intervention/treatment|
|Fanconi Anemia||Genetic: microarray analysis Procedure: biopsy|
- Describe the complete hematopoietic transcriptomes of Fanconi cells of every common complementation group (e.g., A, C, G, and F) as well as transcriptomes of neoplastic cells derived from bone marrow of patients with Fanconi anemia.
- Define large-scale dynamic gene expression data in these patients.
OUTLINE: This is a multicenter study.
Patients and healthy volunteers undergo bone marrow aspiration or biopsy for biological studies. Samples are analyzed for gene expression profiles using microarray assays.
PROJECTED ACCRUAL: A total of 80 patients and 10 healthy volunteers will be accrued for this study.
|Study Type :||Observational|
|Actual Enrollment :||90 participants|
|Official Title:||Analysis of Fanconi Anemia Gene Function by Microarray Analysis of Bone Marrow Cells|
|Study Start Date :||March 2002|
|Actual Primary Completion Date :||September 2007|
|Actual Study Completion Date :||September 2007|
- Comparison of Fanconi anemia (FA) hematopoietic cells vs normal hematopoietic cells
- Comparison of FA hematopoietic cells from children with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) vs children (siblings) with FA but without MDS/AML
- Comparison of FA cells from different complementation groups
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00896740
|United States, Oregon|
|Knight Cancer Institute at Oregon Health and Science University|
|Portland, Oregon, United States, 97239-3098|
|Principal Investigator:||Grover C. Bagby, MD||OHSU Knight Cancer Institute|